Pharma channel feed – Endpoints News

Pharma channel feed

New study looks at FDA's use of social media to communicate on drug safety

8 years ago

Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform

8 years ago

On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product profitability

8 years ago

After bumpy 2017, Celgene CEO says taking risk is the only way forward

8 years ago

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars

8 years ago

Teva inks $200M global licensing deal with migraine rival Alder

8 years ago

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

8 years ago

Pfizer is axing its neurosciences division, laying off 300 and discarding new drugs

8 years ago

China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

8 years ago

Neurodegeneration star Denali nabs a cash-rich, $1B-plus Alzheimer’s partnership with Takeda

8 years ago

SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing

8 years ago

On a roll, MacroGenics allies with Roche on a bispecific development campaign

8 years ago

Allergan axing 1,000-plus jobs, prepping for a painful onslaught of Restasis knockoffs

8 years ago

Pfizer doubles down on Sangamo’s zinc finger tech, adding ALS to a mix of gene therapy alliances

8 years ago

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

8 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

8 years ago

Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race

8 years ago

The FDA just approved the 46th new drug of the year — a record high for the past decade

8 years ago

J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO

8 years ago

Kymriah, Yescarta found 'cost-effective' in treating cancer, despite high price

8 years ago

Merck, Pfizer make a late — very late — arrival at the SGLT2 party for diabetes

8 years ago

A US senator calls out a little biotech for price gouging. But will it change anything?

8 years ago

First page Previous page 311 312 313314315 316 317 Next page Last page